Background {#Sec1}
==========

Sepsis and multiple organ failure (MOF) are the main causes of death in intensive care units (ICUs). There is ample evidence that platelets play an important role in the progression of MOF in critically ill patients \[[@CR1]--[@CR5]\]. At cellular level, platelets have a significant influence on inflammatory processes by releasing cytokines, chemokines, and lipid mediators that have pro- or anti-inflammatory properties \[[@CR6]--[@CR11]\], activating the complement system \[[@CR12], [@CR13]\]. Other platelet effects include releasing antimicrobial proteins and together with neutrophils trapping bacteria \[[@CR10], [@CR14]--[@CR17]\] and mediating adhesion to monocytes, neutrophils, and endothelial cells that lead to cellular functions such as production of cytokines, and reactive oxygen as well as recruitment and immigration of leukocytes at the site of tissue damage \[[@CR7], [@CR10], [@CR11], [@CR18]\]. Hence, the question arose whether aspirin may have a beneficial effect in critically ill patients. Several observational studies have shown that antiplatelet drugs reduce such biomarkers as C-reactive protein, soluble CD62P, and CD54, pro-inflammatory cytokines, and platelet leukocyte conjugate in these patients \[[@CR19]--[@CR23]\]. The aim of the study was to assess the association between aspirin therapy during ICU admission and all-cause mortality in a cohort of critically ill medical-surgical patients.

Methods {#Sec2}
=======

Setting {#Sec3}
-------

The study was a retrospective cohort study, conducted in the adult medical-surgical ICU at King Abdulaziz Medical City, a tertiary-care academic referral center in Riyadh, Saudi Arabia. The ICU admitted medical, surgical, and trauma patients, and operated as a closed unit with 24-h, 7-day onsite coverage by critical care board certified intensivists \[[@CR24]\]. The nurse-to-patient ratio in the unit was approximately 1:1.2.

Study design {#Sec4}
------------

This was a post-hoc analysis of two randomized controlled Trials (ISRCTN07413772 and ISRCTN96294863). The first trial was conducted between January 2004 and March 2006. It included 523 patients, comparing intensive insulin therapy (IIT) (for patients with a blood glucose level of 4.4--6.1 mmol/L or 80--110 mg/dl) to conventional insulin therapy (CIT) (for patients with a blood glucose level of 10--11.1 mmol/L or 180--200 mg/dl) \[[@CR25]\]. The trial showed no significant difference in ICU mortality between the IIT and CIT groups (13.5 % vs. 17.1 %, *p* = 0.3). Hypoglycemia occurred more frequently with intensive insulin therapy (28.6 % vs. 3.1 % of patients; *p* = 0.0001) \[[@CR23]\]. The second trial, conducted between April 2006 and January 2008, included 240 patients and assessed the effects on outcomes of permissive underfeeding (a caloric goal of 60--70 % of the calculated requirement) versus target feeding (caloric goal of 90--100 % of the calculated requirement) with either IIT or CIT in critically ill patients \[[@CR26]\]. The study found no difference between the two groups in 28-day mortality (18 % vs. 23 %, *p* = 0.34) \[[@CR26]\]. However, hospital mortality was lower in the permissive underfeeding compared with the target-feeding group (30 % vs. 43 %, *p* = 0.04) \[[@CR26]\]. All the patients enrolled in the original two trials were included in this study. In brief, these patients were ≥18 year-old with expected ICU length of stay(LOS) of \>48 h. Patients who were pregnant, had do-not-resuscitate status within 24 h of admission, were terminally ill or admitted to the ICU after cardiac arrest, seizures, liver transplantation or burn injury were excluded. This study was approved by the Ministry of National Guard Health Affairs (NGHA) /King Abdullah International Medical Research Center (KAIMRC) Institutional Review Board. The consent for the present analysis was waived because of the observational nature of the study.

Aspirin therapy {#Sec5}
---------------

Data of aspirin therapy in the ICU were collected from the Pharmaceutical Care database and was matched and combined with the original clinical database. Aspirin therapy was either as a continuation of a pre-ICU prescription or a newly prescribed medication in the ICU per the treating team discretion, such as for patients admitted with stroke or acute coronary syndrome.

Data collection {#Sec6}
---------------

The following data were retrieved from the two original studies: age, gender, Acute Physiology and Chronic Health Evaluation (APACHE II) score \[[@CR27]\], sequential organ failure assessment (SOFA) score \[[@CR28]\], chronic co-morbidities (chronic liver, chronic cardiovascular, chronic respiratory, chronic renal and chronic immunocompromised) as defined by the APACHE II system, history of diabetes mellitus, admission diagnosis category (respiratory, cardiovascular, neurological, other medical, non-operative trauma and post-operative), mechanical ventilation (MV), sepsis and severe sepsis on admission. We also documented the statin use, bilirubin level, serum creatinine level, admission Glasgow Coma Scale (GCS) score \[[@CR28]\], vasopressor use, The arterial partial pressure of O~2~ and the fraction of inspired oxygen (PaO~2~/FiO~2~) ratio, international normalization ratio (INR), and platelet count.

Outcomes {#Sec7}
--------

The primary outcomes were all-cause ICU mortality and hospital mortality. Secondary endpoints included the development of severe sepsis during the ICU stay, ICU and hospital LOS, and MV duration.

Statistical analysis {#Sec8}
--------------------

Statistical analysis was carried out using the Statistical Analysis Software (SAS, release 9, SAS Institute, Cary, NC, 2005). We compared patients who received aspirin during their ICU admission (aspirin group) to those who did not (non-aspirin group). Categorical data were presented as frequency with percent, whereas continuous variables were presented as mean with and standard deviation. Baseline characteristics and outcome variables were compared using the Chi-square test for nominal data and the Student *t* -test for continuous data. Due to the non-random allocation to aspirin use and significant differences between the groups in terms of baseline characteristics, a propensity score was calculated using the variables related to the aspirin exposure and outcome. These variables were age, sex, diabetes history, admission category, APACHE II score, chronic respiratory disease, chronic renal disease, chronic immunosuppression, creatinine, PaO~2~/FiO~2~ ratio, platelets, and statins Furthermore, the association between aspirin therapy each outcome was assessed by performing multivariate logistic regression analysis adjusting for the generated propensity score. Additionally, we carried out stratified analyses by age, gender, admission category, APACHE II, history of diabetes, the presence of chronic cardiac disease, vasopressor therapy, sepsis, severe sepsis and septic shock, creatinine, platelet count, bilirubin, INR, GCS, ICU LOS stay, MV, PaO~2~/FiO~2~ ratio, and the type of statins to detect any effect modification of the association between aspirin therapy and different outcome measures based on any of these factors. The medians of the continuous variables were used for categorization. The results of the multivariate analysis were presented as adjusted odds ratios (aOR) or point estimate with the 95 % confidence intervals (CI). We tested for interaction to assess effect modification between subgroups. Statistical significance was defined as *p* value ≤ 0.05.

Results {#Sec9}
=======

Patients characteristics {#Sec10}
------------------------

Of the 763 patients enrolled in the study, 154 (20.2 %) received aspirin at a dose of 81 mg daily during their ICU stay. Table [1](#Tab1){ref-type="table"} presents the comparison in baseline characteristics between aspirin and non-aspirin group. Patients who received aspirin were older, more likely to be males, had higher APACHE II scores, more likely to be on statins, with higher serum creatinine, more likely to be diabetics, with chronic cardiac, renal and respiratory illnesses and also with with lower platelets. When adjusted for propensity score, all these differences became insignificant.Table 1Baseline characteristics of the aspirin and non-aspirin therapy groupsVariableAspirin\
*N* = 154Non-aspirin\
*N* = 609Crude\
*P* valuePS adjusted\
*P*-ValueAge (yrs) mean ± SD65 ± 16.548.8 ± 21.7\<0.00010.88Gender, n (%) Female56 (36.4)152 (25)0.0050.97 Male98 (63.6)457 (75.1)Diabetes, n (%)102 (66.2)201 (33.8)0.00010.22Admission category, n (%) Non-operative145 (94.2)495 (81.3)0.00010.21 Post-operative9 (5.8)114 (18.7)APACHE II, mean ± SD26.5 ± 7.222.9 ± 8.2\<0.00010.67Mechanical ventilation, n (%)135 (87.7)548 (90)0.400.93SOFA on day 1, mean ± SD9.3 ± 3.39.2 ± 3.50.820.52Sepsis, n (%)47 (30.5)147 (24.1)0.1040.68Chronic respiratory disease, n (%)43 (27.9)114 (18.7)0.0110.19Chronic cardiac disease n (%)76 (49.4)81 (13.3)\<0.00010.86Chronic liver disease n (%)9 (5.8)45 (7.4)0.500.54Chronic immunosuppression n (%)11 (7.1)55 (9.1)0.450.30Chronic renal disease n%38 (24.7)65 (10.7)0.00010.43GCS, mean ± SD9.0 ± 4.28.6 ± 4.10.230.70Vasopressor, n (%)106 (68.8)390 (64.1)0.260.36PaO~2~/FiO~2~ ratio, mean ± SD200 ± 98221 ± 1190.040.88Statin use n%74 (48.1)33 (5.4)\<0.00010.83Bilirubin (μmol/L), mean ± SD^a^31.2 ± 69.436.1 ± 700.500.26Creatinine (μmol/L), mean ± SD^a^199.9 ± 171.2148.8 ± 146.50.00020.15INR, mean ± SD1.5 ± 0.81.5 ± 0.90.730.26Platelet, x 10^9^/L mean ± SD193.1 ± 121247.9 ± 133.3\<0.00010.048*P*-values are provided for the differences between the two groups significant before and after propensity score adjustment*APACHE* Acute physiology and chronic health evaluation, *GCS* Glasgow coma scale, *INR* International normalized ratio, *PS* propensity score, *SOFA* Sequential Organ Failure Assessment^a^To convert to conventional units in mg/dL, divide by 88.4 for creatinine and 17.1 for bilirubin

Outcomes {#Sec11}
--------

Table [2](#Tab2){ref-type="table"} summarized the association between aspirin therapy and mortality using multivariate analysis adjusted for propensity score. Aspirin therapy was not associated with ICU mortality (adjusted OR 1.18, 95 % CI 0.69--2.02, *P* = 0.55) nor with hospital mortality (adjusted OR 0.95, 95 % CI 0.61--1.50, *P* = 0.82). On the other hand, aspirin therapy was associated with higher risk of ICU-acquired severe sepsis (adjusted OR 1.70, 95 % CI 1.08--2.70, *P* = 0.02), increased MV duration (adjusted point estimate 2.7 days, 95 % CI 0.51--4.9, *P* = 0.02), and ICU length of stay (adjusted point estimate 2.67 days, 95 % CI 0.38--4.10, *P* = 0.02).Table 2Outcomes results of the aspirin and non-aspirin therapy groupsVariableAspirin\
*N* = 154Non-aspirin\
*N* = 609Crude odds ratioAdjusted odds ratioOR95 % CI*P* valueOR95 % CI*P* valueCategoricalICU mortality n (%)32 (20.8)95 (15.6)1.420.91,2.220.121.180.69, 2.020.55Hospital mortality n (%)62 (40.3)180 (29.6)1.611.11,2.320.010.950.61, 1.500.82Sepsis n (%)56 (36.4)256 (42.04)0.790.55,1.360.201.180.76, 1.840.45Severe sepsis n (%)51 (33.1)182 (29.9)1.160.80,1.700.441.701.08, 2.700.0228 day mortality n (%)19 (30.7)31 (17.4)2.091.08,4.070.021.410.65, 3.050.39180 day mortality n (%)50 (34.1)128 (22.7)1.751.18, 2.600.0050.720.43, 1.210.22Continuouspoint estimate95 % CI*P* valuepoint estimate95 % CI*P* valueMV duration (days)11.17 ± 14.929.60 ± 9.051.58−0.28, 3.440.092.70.51, 4.900.02ICU LOS (days)12.4 ± 15.210.8 ± 9.51.7−0.27, 3.580.092.670.38,4.960.02Hospital LOS (days)65.6 ± 107.258.4 ± 81.77.22−8.3, 22.70.3612.5−5.90, 30.960.18*CI* Confidence interval, *MV* Mechanical ventilation, *OR* Odds ratio

Table [3](#Tab3){ref-type="table"} shows the association between aspirin therapy and all-cause hospital mortality in several subgroups of patients. Aspirin therapy was not associated with lower hospital mortality among any of the studied subgroups.Table 3Adjusted hospital mortality risk for subgroupsVariableAdjusted odds ratio95 % confidence interval*P* value for interactionAll patients0.950.60, 1.490.82Age ≤ 580.760.25, 1.990.12Age \> 580.990.60, 1.67Males0.650.35, 1.210.26Females1.590.78, 3.24Diabetes, yes0.810.46, 1.420.002no1.090.52, 2.29APACHE ≤ 230.370.13, 1.110.96APACHE \> 231.140.67, 1.94Sepsis present0.890.41,1.930.16Sepsis absent1.040.59, 1.82Severe sepsis present1.230.58, 2.600.12Severe sepsis absent0.700.39, 1.27Non operative0.950.60, 1.500.88Post-operative0.340.02, 4.43Chronic Respiratory diseaseYes1.180.54, 2.600.39No0.800.45, 1.42Chronic Cardiac diseaseYes0.920.47, 1.800.21No0.750.39, 1.43Chronic Renal diseaseYes0.810.30, 2.200.55No0.960.57, 1.60Chronic liver diseaseYes0.280.03, 2.240.21No1.050.66, 1.66Chronic immunosuppressionYes0.760.15, 3.730.14No1.0030.63, 1.61Platelets × 10^9^/L ≤ 1840.710.35, 1.460.73Platelets × 10^9^/L \> 1841.340.74, 2.44Bilirubin (μmol/l) ≤ 160.760.36, 1.620.16Bilirubin (μmol/l) \> 160.870.40, 1.90Creatinine (μmol/l) ≤ 1020.970.41, 2.280.39Creatinine (μmol/l) \> 1020.830.49, 1.42Statin users1.170.50, 2.740.74Statin non-users0.750.42, 1.32PaO~2~/FiO~2~ ratio \>2000.430.19,0.970.14PaO~2~/FiO~2~ ratio \<2001.560.88,2.79^a^Adjusted for propensity score which was calculated from age, sex, diabetes, admission category, APACHE, chronic respiratory disease, chronic renal disease, chronic immunosuppression, creatinine, PaO~2~/FiO~2~ ratio, platelets, and statin use

Discussion {#Sec12}
==========

The present study showed that the use of aspirin in critically ill patients was not associated with lower mortality, but rather with increased morbidity.

Various retrospective clinical studies have shown that low-dose aspirin was associated with reduced mortality. Winning et al. conducted a single center retrospective cohort study on 615 critically ill patients, 25 % of whom were receiving antiplatelet drugs (aspirin or clopidogrel; 129 received aspirin in a dose of \< 160 mg) and observed that patients on anti-platelets had lower ICU mortality (OR 0.19, 95 %, CI 0.12--0.33) on multivariable analysis \[[@CR29]\]. The same investigators conducted a study on patients with community acquired pneumonia and found a decrease in the length of hospital stay in association with aspirin therapy \[[@CR30]\]. Moreover, a large cohort study of ICU patients (*n* = 7,945) showed that low-dose aspirin was associated with reduced mortality among patients with systemic inflammatory response syndrome and sepsis although the risk of renal injury increased \[[@CR31]\]. On the other hand, Valerio-Rojas et al. performed a retrospective cohort study and found that antiplatelet therapy was not associated with decrease in hospital mortality or ICU mortality \[[@CR32]\]. The current study found no statically significant difference between the two groups in the ICU, hospital mortality after adjusting for the propensity to receive aspirin therapy. Rather, our study shows aspirin use is associated with higher risk of developing severe sepsis during ICU stay and an increase in the duration of mechanical ventilation and ICU length of stay.

Aspirin use has been studied for its possible effect in reducing the risk of acute lung injury (ALI). Erlich et al. found that pre-hospitalization antiplatelet therapy was associated with a reduced incidence of ALI (OR 0.34, 95 % CI 0.13--0.88) \[[@CR33]\]. Another observational study had similar findings \[[@CR32]\]. Another ICU cohort study found that aspirin potentiated the effect of statins in reducing ALI and sepsis \[[@CR34]\]. More recently, in a secondary analysis of the Validating Acute Lung Injury Markers for Diagnosis study, Chen et al. found that prehospital aspirin use was associated with a decreased risk of acute respiratory distress syndrome (OR 0.66, 95 % CI, 0.46--0.94) \[[@CR35]\]. However, Kor et al. conducted a large multicenter observational study that included 20 ICUs in the US and two ICUs in Turkey failed to confirm the beneficial effect of aspirin on ALI after adjusting for propensity score to receive aspirin therapy \[[@CR36]\]. Our study did not examine the association with the incidence with ALI. However, it showed higher risk of ICU-associated severe sepsis. In addition, it showed that aspirin therapy was not associated with lower mortality in patients with ALI (OR 1.56, 95 % CI 0.88--2.79).

Aspirin has multiple effects in critically ill patients. As antiplatelet drugs irreversibly inhibit platelet function, they hinder their activation and surface expression of adhesion molecules like selectins and GPIIb IIIa receptors which are key in the formulation of microvascular thrombus \[[@CR37]\]. Once microvascular thrombosis is formed, it causes ischemia that contributes to tissue injury and multiple organ dysfunction syndrome \[[@CR38], [@CR39]\]. Also, platelet inactivation attenuates the secretion of inflammatory mediators \[[@CR7], [@CR9]\], depresses their interaction with immune cells \[[@CR40]\] and hence modulates the adverse effects associated with the inflammatory reaction \[[@CR41]\]. Additionally, aspirin stimulates the synthesis of 15-epi-lipoxin A4, in which it increases the synthesis of nitric oxide through endothelial nitric oxide synthase and inducible nitric oxide synthase \[[@CR42]\]. Nitric oxide inhibits the interactions between leucocytes and endothelial cells, decreasing poly-morph neutrophil recruitment \[[@CR43]\]. Another putative effect of aspirin is the inhibition of the nuclear factor kappa-B \[[@CR44]\], which plays an essential role in immune and inflammatory responses \[[@CR45]\]. The lack of beneficial effect of aspirin may be a reflection of the interaction on these multiple pathways, where a possibly positive effect may be negated by a negative effect.

Our study should be interpreted in light of its strengths and limitations. The strengths of our study include being a nested cohort study within randomized controlled trials with prospective data collection and all the patients on the treatment group were on aspirin 81 mg. Yet, our study has several limitations, which includes its post-hoc design with the concern of unmeasured bias and confounders. To overcome this concern, we performed adjusted analysis using the propensity score. Other limitations include its monocenter nature, and the lack of data on the duration of aspirin therapy prior to ICU admission, cause of aspirin prescription and data on other antiplatelet agents, platelet transfusion, and aspirin side effects. Additionally, we have no data on bleeding risk or the development of ALI.

Conclusions {#Sec13}
===========

Our study show that continuing aspirin therapy during ICU stay was not associated with reduction in ICU or hospital mortality in critically ill patients, but rather with an increased morbidity. This adds to the conflicting data and confirms the need for randomized, controlled trials to verify the relationship between aspirin therapy and the outcomes of critically ill patients. Currently, there is an ongoing trial of aspirin 200 mg once daily for 14 days compared with placebo in adult patients with severe sepsis and/or septic shock (NCT01784159). Furthermore, another multicenter randomized clinical trial is evaluating aspirin use in preventing ARDS (NCT01504867). We hope that these ongoing clinical trials will provide clear answers on the role of aspirin therapy in critical illness.

ALI

:   Acute lung injury

ARDS

:   Acute respiratory distress syndrome
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:   Multiple organ failure
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